Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certican versus Myfortic with Neoral in de novo renal transplant recipients
2005-002854-22Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus, mycophenolate sodium and cyclosporine in kidney allograft rejection (3 arms), sponsored by Novartis. Primary endpoint: Composite efficacy failure rate at 12 months. Started Sep 2005; status: completed.
02
Drugs
everolimusmycophenolate sodiumcyclosporine
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2005-002854-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002854-22.